



ESP VIRTUAL MEETING PROGRAMME

September 18th 2020

Time Zone: Central European Time (CET)

 <p><i>Industry Symposium I</i></p> <p>IMPROVING SUPPORT FOR CYSTINOSIS PATIENTS BY OPTIMISING COMMUNICATION CHANNELS</p> <p><i>Introduction to the value of a multidisciplinary team approach to the care of the cystinosis patient - Jun Oh</i></p> <p><i>How does communication benefit your patient? - Jun Oh - Fiona Bathgate</i></p> <ul style="list-style-type: none"> • What are its characteristics? • How members of the multidisciplinary team communicate differently • How optimal communication offers best support for your patient <p><i>Cystinosis & Me: a new tool in patient communication - Detlef Bockenhauer</i></p> <ul style="list-style-type: none"> • Encouraging patient empowerment • Improving overall patient compliance • Integrating with an adolescent's daily life" <p><i>Conclusion - Detlef Bockenhauer – Jun Oh</i></p> <p>Q&A</p>	<p>11:00 - 12:00</p> <p>11:00 – 11:05</p> <p>11:05 – 11:25</p> <p>11:25 – 11:45</p> <p>11:45 – 11:50</p> <p>11:50 – 12:00</p>
<p>Coffee Break</p>	
 <p><i>Industry Symposium II</i></p> <p>OXALATE – FROM TOXIC AGENT TO PREDICTIVE MARKER IN PRIMARY HYPEROXALURIA TYPE 1 (PH1)</p> <p><i>Welcome & introduction - Jun Oh</i></p> <p><i>Excess oxalate: The damage and the consequences - Oliver Devuyt</i></p> <ul style="list-style-type: none"> • The harm caused by elevated levels of urinary oxalate (UOx) • Differences between primary and secondary hyperoxaluria • The clinical benefits of lowering UOx and plasma oxalate (POx) in patients with PH1 • Utilising UOx and POx to predict outcome and measure treatment effect <p><i>The management of high oxalate in PH1 - Sally-Ann Hulton</i></p> <ul style="list-style-type: none"> • Current treatment strategies • New treatment approaches in development for PH1 <p>Q&A</p>	<p>12:05 – 13:05</p> <p>12:05 – 12:10</p> <p>12:10 – 12:30</p> <p>12:30 – 12:50</p> <p>12:50 – 13:05</p>
<p>Coffee Break</p>	
 <p><i>Industry Symposium III</i></p> <p><i>Mind the gap: planning for long-term success in cystinosis care</i></p> <p>Gema Ariceta</p>	<p>13:10 – 13:30</p>
<p>Coffee Break</p>	
 <p><i>Industry Symposium IV</i></p> <p><i>Long-term outcomes of dRTA</i></p> <p>Detlef Bockenhauer</p> <p><i>Moderated by Rezan Topaloglu</i></p>	<p>13:35 – 13:55</p>
<p>BREAK</p>	

Introduction and Welcome Rezan Topaloglu (ESPN President) Dieter Haffner (ESPN Assistant President)	14:15 - 14:20
“COVID-19 and its impact on pediatric nephrology” Giovanni Montini <i>moderated by Martin Christian</i>	14:20 - 14:50
Coffee Break	14:50 – 14:55
“State of the art in nephrotic syndrome” Arvind Bagga <i>moderated by Francesco Emma</i>	14:55 – 15:25
Coffee Break	15:25 – 15:30
“Linking glomerular disease and basement membrane biology” Rachel Lennon <i>moderated by Elena Levtchenko</i>	15:30 – 16:00
Coffee Break	16:00 – 16:05
“Renal replacement therapy: a historical perspective” Otto Mehls <i>moderated by Franz Schaefer</i>	16:05 – 16:35
Videos in memory of Michel Broyer, Lluís Callis, Karl Schaefer	16:35 – 16:45
Coffee Break	16:45 – 16:50
ESPN General Assembly Concluding comments and welcome to new ESPN Council members & Results of Research Grants Applications Rezan Topaloglu (ESPN President) Dieter Haffner (ESPN Assistant President)	16:50 - 17:15
ESPN 2021 Amsterdam video presentation	17:15 - 17:25